Investigations on factors affecting chitosan for dissolution enhancement of oxcarbazepine by spray dried microcrystal formulation with an experimental design approach

Drug Development and Industrial Pharmacy

Volumn 33, Issue 9, 2007, Pages 1008-1023

  Rane, Yogesh M ^a   Mashru, Rajshree C ^a   Sankalia, Mayur G ^a   Sutariya, Vijay B ^a   Shah, Punit P ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Chitosan; Desirability function; Enhancement; Fractional factorial design; Oxcarbazepine (OCBZ) microcrystals; Scanning electron microscopy (SEM)

Indexed keywords

CHITOSAN; OXCARBAZEPINE; POLYMER;

ARTICLE; ASPIRATION; CONCENTRATION (PARAMETERS); CRYSTAL; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG EFFECT; DRUG FORMULATION; EXPERIMENTAL DESIGN; FACTORIAL DESIGN; FEEDING; INDEPENDENT VARIABLE; MODEL; MORPHOLOGY; MULTIPLE LINEAR REGRESSION ANALYSIS; PARTICLE SIZE; RESPONSE SURFACE METHOD; RESPONSE VARIABLE; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; TEMPERATURE; TOPOGRAPHY; WETTABILITY;

ANTICONVULSANTS; CARBAMAZEPINE; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; CRYSTALLIZATION; DRUG CARRIERS; LINEAR MODELS; MICROSPHERES; PARTICLE SIZE; POLYMERS; POWDERS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE; WETTABILITY;

EID: 34648821975     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040601179749     Document Type: Article

References (49)

1. Abberger, T., Seo, A., & Schaefer, T. (2002). The effect of droplet size and powder particle size on the mechanisms of nucleation and growth in fluid bed melt agglomeration. Int. J. Pharm., 249, 185-197.
2. Acarturk, F., Sencan, A., & Celebi, N. (1993a). Enhancement of the dissolution of spironolactone with chitosan and low molecular weight gelatin. STP Pharma. Sci., 3, 369-373.
3. Acarturk, F., Sencan, A., & Celebi, N. (1993b). Evaluation of the effect of low molecular weight chitosan on the solubility and dissolution characteristics of spironolactone. Pharmazie., 48, 605-607.
4. Adler, M., & Lee, G. (1999). Stability and surface activity of lactate dehydrogenase in spray dried trehalose. J. Pharm., Sci, 88, 199-208.
5. Ambike, A. A., Mahadik, K. R., & Paradkar, A. (2005). Spray-dried amorphous solid dispersions of simvastatin, a low tg drug: in vitro and in vivo evaluations. Pharm. Res., 22, 990-998.
6. Asada, M., Takahashi, H., Okamoto, H., Tanino, H., & Danjo, K. (2004). Theophylline particle design using chitosan by the spray drying. Int. J. Pharm., 270, 167-174.
7. Bodek, K. H. (2002). Effect of microcrystalline chitosan on the solubility of ibuprofen. Acta Pol Pharm., 59, 105-108.
8. Byrn, S. R., Xu, W., & Newman, A. W. (2001). Chemical reactivity in solid-state Pharm.aceuticals: formulation implications. Adv. Drug Deliv. Rev., 48, 115-136.
9. Chidavaenzi, O. C., Buckton, G., & Koosha, F. (2001). The effect of co-spray drying with polyethylene glycol 4000 on the crystallinity and physical form of lactose. Int. J. Pharm., 216, 43-49.
10. Christensen, K. L., Pedersen, G. P., & Kristensen, H. G. (2001). Preparation of redispersible dry emulsions by spray drying. Int. J. Pharm., 212, 187-194.
11. Cilurzo, F., Minghetti, P., Casiraghi, A., & Montanari, L. (2002). Characterization of nifedipine solid dispersions. Int. J. Pharm., 242, 313-317.
12. Corrigan, O. I. (1995). Thermal analysis of spray dried products. Thermo. Acta, 248, 245-258.
13. Corrigan, D. O., Healy, A. M., & Corrigan, O. I. (2002). The effect of spray drying solutions of polyethylene glycol (PEG) and lactose/PEG on their physicochemical properties. Int. J. Pharm., 235, 193-205.
14. Doherty, C., & York, P. (1989). The in-vitro pH-dissolution dependence and in-vivo bioavailability of frusemide-PVP solid dispersions. J. Pharm. Pharmacol., 41, 73-78.
15. Feeley, J. C., York, P., Sumby, B. S., & Dicks, H. (1998). Determination of surface properties and flow characteristics of salbutamol sulphate, before and after micronisation. Int. J. Pharm., 172, 89-96.
16. Giunchedi, P., Gavini, E., Palmieri, G. F., & Bonacucina, G. (2000). Tabletted polylactide microspheres prepared by a w/o emulsion - spray drying method. J. Microencapsul., 17, 711-720.
17. Giunchedi, P., Juliano, C., Gavini, E., Cossu, M., & Sorrenti, M. (2002). Formulation and in vivo evaluation of chlorhexidine buccal tablets prepared using drug loaded chitosan microspheres. Eur. J. Pharm. Biopharm., 53, 233-239.
18. Gohel, M. C., & Patel, L. D. (2003). Processing of nimesulide-PEG 400-PGPVP solid dispersions: preparation, characterization, and in vitro dissolution. Drug Dev. Ind. Pharm., 29, 299-310.
19. Hancock, B. C., & Zografi, G. (1997). Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci., 86, 1-12.
20. Hou, W. M., Miyazaki, S., Takada, M., & Komai, T. (1985). Sustained release of indomethacin from chitosan granules. Chem. Pharm. Bull., 33, 3986-3992.
21. Ishikawa, T., Watanabe, Y., Takayama, K., Endo, H., & Matsumoto, M. (2000). Effect of hydroxypropylmethylcellulose (HPMC) on the release profiles and bioavailability of a poorly water-soluble drug from tablets prepared using macrogol and HPMC. Int. J. Pharm., 202, 173-178.
22. Kapsi, S. G., & Ayres, J. W. (2001). Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. Int. J. Pharm., 229, 193-203.
23. Kaushal, A. M., Gupta, P., & Bansal, A. K. (2004). Amorphous Drug Delivery Systems: Molecular Aspects, Design and Performance. Crit. Rev. Therap. Drug Carri. Syst., 21, 133-193.
24. Lian, Y. (2001). Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv. Drug Deliv. Rev., 48, 27-42.
25. Lobenberg, R., & Amidon, G. L. (2000). Modern bioavailability, bioequivalence and and biopharmaceutics classification system: new scientific approaches to international regulatory standards. Eur J Pharm. Biopharm., 50, 3-12.
26. Mashru, R. C., Sutariya, V. B., Sankalia, M. G., Sankalia, J. M., & Parikh, P. P. (2005). Development and evaluation of fast dissolving film of salbutamol sulphate. Drug Dev. Ind. Pharm., 1, 25-34.
27. Maury, M., Murphy, K., Kumar, S., Shi, L., & Lee, G. (2005). Effects of process variables on the powder yield of spray-dried trehalose on a laboratory spray-dryer. Eur. J. Pharm. Biopharm., 59, 565-573.
28. Menon, A., Dhodi, N., Mandella, W., & Chakrabarti, S. (1996). Identifying fluid bed parameters affecting product variability. Int. J. Pharm., 140, 207-218.
29. Mitchell, S. A., Reynolds, T. D., & Dasbach, T. P. (2003). A compaction process to enhance dissolution of poorly water-soluble drugs using hydroxypropyl methylcellulose. Int. J. Pharm., 250, 3-11.
30. Nazzal, S., Nutan, M., Palamakula, A., Shah, R., Zaghloul, A., & Khan, M. A. (2002.). Optimization of a self-nanoemulsified tablet dosage form of Ubiquinone using response surface methodology: effect of formulation ingredients. Int. J. Pharm., 240, 103-114.
31. Oxcarbazepine. New medicines on the market Produced by the UK Medicines Information Pharmacists Group (Aug 2000). http://www.ukdipg.org.uk/stage4.htm.
32. Paradkar, A. R., Ambike, A. A., Jadhav, B. K., & Mahadik, K. R. (2004). Characterization of curcumin-pvp solid dispersions obtained by spray drying. Int. J. Pharm., 271, 281-286.
33. Portero, A., Remuñan-Lopez, C., & Vila-Jato, J. L. (1998). Effect of chitosan and chitosan glutamate enhancing the dissolution properties of the poorly water soluble drug nifedipine. Int. J. Pharm., 175, 75-84.
34. Qi, R., & Ping, Q. N. (2004). Gastrointestinal absorption enhancement of insulin by administration of enteric microspheres and SNAC to rats. J. Microencapsul., 21, 37-45.
35. Rambali, B., Baert, L., & Massart, D. L. (2001). Using experimental design to optimize the process parameters in a fluid bed granulation on a semi-full scale. Int. J. Pharm., 220, 149-160.
36. Rasenack, N., Hartenhauer, H., & Muller, B. W. (2003). Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int. J. Pharm., 254, 137-145.
37. Rasenack, N., & Muller, B. W. (2002). Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm. Res., 19, 1894-1900.
38. Ritthidej, G. C., Chomto, P., Pummangura, S., & Menasveta, P. (1994). Chitin and chitosan as disintegrants in paracetamol tablets. Drug Dev. Ind. Pharm., 20, 2109-2134.
39. Rotthäuser, B., Kraus, G., & Schmidt, P. C. (1998). Optimization of an effervescent tablet formulation using a central composite design optimization of an effervescent tablet formulation containing spray dried L-leucine and polyethylene glycol 6000 as lubricants using a central composite design. Eur. J. Pharm. Biopharm., 46, 85-94.
40. Sawayanagi, Y., Nambu, N., & Nagai, T. (1982). Dissolution properties and bioavailability of griseofulvin from ground mixtures with chitin or chitosan. Chem. Pharm. Bull., 30, 4454-4467.
41. Sawayanagi, Y., Nambu, N., & Nagai, T. (1983). Dissolution properties and bioavailability of phenytoin from ground mixtures with chitin or chitosan. Chem. Pharm. Bull., 31, 2062-2068.
42. Schott, H. (1985). Colloidal dispersions. Philadelphia: The Philadelphia College of Pharmacy and Science.
43. Sertsou, G., Butler, J., Scott, A., Hempenstall, J., & Rades, T. (2002). Factors affecting incorporation of drug into solid solution with HPMCP during solvent change co-precipitation. Int. J. Pharm., 245, 99-108.
44. Shiraishi, S., Arahira, M., Imai, T., & Otagiri, M. (1990). Enhancement of dissolution rates of several drugs by low molecular chitosan and alginate. Chem. Pharm. Bull., 38, 185-187.
45. Upadrashta, S. M., Katikaneni, P. R., & Nuessle, N. O. (1992). Chitosan as a tablet binder. Drug Dev. Ind. Pharm., 18, 1701-1708.
46. Vertommen, J., & Kinget, R. (1997). The influence of five selected processing and formulation variables on the particle size, particle size distribution and friability of pellets produced in a rotary processor. Drug Dev. Ind. Pharm., 23, 39-46.
47. Wiedmann, T. S., DeCastro, L., & Wood, R. W. (1997). Nebulization of NanoCrystals™: Production of a Respirable Solid-in-Liquid-in-Air Colloidal Dispersion. Pharm. Res., 14, 112-116.
48. Yamada, T., Saito, N., Anraku, M., Imai, T., & Otagiri, M. (2000). Physicochemical characterization of a new crystal form and improvements in the pharmaceutical properties of the poorly water-soluble antiosteoporosis drug 3,9-bis(N,N-dimethylcarbamoy-loxy)-5H-benzofuro[3,2-c]quinoline-6-one (KCA-098) by solid dispersion with hydroxypropylcellulose. Pharm. Dev. Technol., 5, 443-454.
49. Yu, L. X., Amidon, G. L., Polli, J. E., Zhao, H., Mehta, M. U., Conner, D. P., Shah, V. P., Lesko, L. J., Chen, M. L., Lee, V. H., & Hussain, A. S. (2002). Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res., 19, 921-925.